Skip to main content

Table 1 Characteristics of 46,127 non-small cell lung cancer patients

From: Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation

Variables

ICI with conventional therapies

Monotherapies

OTHER (N = 9792)

ICI+CHEMO (N= 3110)

ICI+TARGET (N = 227)

ICI+RT (N = 483)

ICI (N = 15,263)

CHEMO (N = 6420)

TARGET (N = 10,796)

RT (N = 36)

Age

65.6 (9.62)

66.0 (11.5)

68.3 (9.59)

66.9 (10.1)

64.0 (10.7)

67.0 (12.0)

58.9 (11.3)

63.0 (11.9)

Sex

 Female

931 (29.9)

107 (47.1)

117 (24.2)

4569 (29.9)

1856 (28.9)

5837 (54.1)

20 (55.6)

4080 (41.7)

 Male

1954 (62.8)

102 (44.9)

337 (69.8)

9527 (62.4)

3153 (49.1)

3744 (34.7)

14 (38.9)

4424 (45.2)

 Not reported

225 (7.2)

18 (7.9)

29 (6.0)

1167 (7.6)

1411 (22.0)

1215 (11.3)

2 (5.6)

1288 (13.2)

Country

 Germany

378 (12.2)

5 (2.2)

7 (1.4)

684 (4.5)

846 (13.2)

303 (2.8)

2 (5.6)

479 (4.9)

 France

216 (6.9)

14 (6.2)

14 (2.9)

1173 (7.7)

616 (9.6)

441 (4.1)

0 (0)

980 (10.0)

 UK

119 (3.8)

3 (1.3)

2 (0.4)

278 (1.8)

348 (5.4)

1468 (13.6)

1 (2.8)

587 (6.0)

 Japan

896 (28.8)

95 (41.9)

392 (81.2)

5384 (35.3)

914 (14.2)

2570 (23.8)

3 (8.3)

1854 (18.9)

 USA

641 (20.6)

55 (24.2)

22 (4.6)

3651 (23.9)

1636 (25.5)

2413 (22.4)

13 (36.1)

2538 (25.9)

 Others

860 (27.7)

55 (24.2)

46 (9.5)

4093 (26.8)

2060 (32.1)

3601 (33.4)

17 (47.2)

3354 (34.3)

Reporter occupation

 Healthcare professional

1917 (61.6)

161 (70.9)

384 (79.5)

10,342 (67.8)

4730 (73.7)

6573 (60.9)

24 (66.7)

7620 (77.8)

 Non-healthcare professional

1185 (38.1)

60 (26.4)

45 (9.3)

4730 (31.0)

1655 (25.8)

3465 (32.1)

12 (33.3)

1999 (20.4)

 Not reported

8 (0.3)

6 (2.6)

54 (11.2)

191 (1.3)

35 (0.5)

758 (7.0)

0 (0)

173 (1.8)

Year

 2015

21 (0.7)

3 (1.3)

2 (0.4)

576 (3.8)

1113 (17.3)

1446 (13.4)

7 (19.4)

1452 (14.8)

 2016

84 (2.7)

26 (11.5)

11 (2.3)

1880 (12.3)

837 (13.0)

1735 (16.1)

9 (25.0)

1479 (15.1)

 2017

271 (8.7)

45 (19.8)

21 (4.3)

2779 (18.2)

1146 (17.9)

2266 (21.0)

6 (16.7)

1419 (14.5)

 2018

609 (19.6)

58 (25.6)

68 (14.1)

3952 (25.9)

1527 (23.8)

1898 (17.6)

4 (11.1)

2021 (20.6)

 2019

1275 (41.0)

53 (23.3)

251 (52.0)

4163 (27.3)

1223 (19.0)

2370 (22.0)

5 (13.9)

2270 (23.2)

 2020 Q1–2

850 (27.3)

42 (18.5)

130 (26.9)

1913 (12.5)

574 (8.9)

1081 (10.0)

5 (13.9)

1151 (11.8)

IP

 With IP

290 (9.3)

30 (13.2)

446 (92.3)

1579 (10.3)

320 (5.0)

591 (5.5)

13 (36.1)

561 (5.7)

 Without IP

2820 (90.7)

197 (86.8)

37 (7.7)

13,684 (89.7)

6100 (95.0)

10,205 (94.5)

23 (63.9)

9231 (94.3)

  1. Classified variable data are shown as n (%)
  2. IP Interstitial pneumonitis, RT Radiation therapy, CHEMO Chemotherapy, ICI Immune checkpoint inhibitor therapy, TARGET Targeted therapy, OTHER Other therapies not mentioned